Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Strata Critical Medical, Inc. (SRTA)

Strata Q3 revenue rises 50.3% to $74.1 million; net loss narrows to $7.6 million

Positive Impact 3 of 5 earnings Written later

Strata Critical Medical reported third-quarter 2026 results, with revenue up 50.3% year-over-year to $74.1 million, driven mainly by Clinical acquisitions, while Logistics revenue fell 3.5%. The net loss from continuing operations narrowed to $7.6 million from $9.7 million, and the company announced a $20 million share repurchase authorization and reiterated its 2026 guidance. For shareholders, the larger revenue base and improved profit measures are offset by the continuing net loss and weaker Logistics results.

Key points

  • Q3 2026 revenue of $74.1 million, up from $49.3 million a year earlier; Logistics revenue down 3.5% to $44.9 million
  • Net loss from continuing operations of $7.6 million in Q3 2026, versus $9.7 million in Q3 2025
  • Adjusted EBITDA of $9.6 million, a 13.0% margin, versus $4.2 million (8.5%) a year earlier
  • $20 million share repurchase authorization announced; 2026 revenue ($285-295 million) and Adjusted EBITDA ($33-35 million) guidance reiterated

The filing

CompanyStrata Critical Medical, Inc. (SRTA)
Form8-K, current report
Filed with the SECNov 3, 2026, 8:11 AM ET
Accession number0001628280-26-069117

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.